ABSTRACT
Objective To discuss the effect of Human Immunoglobulin for Intravenous Injection in the treatment of neonatal pneumonia treatment and intervention. Methods 100 cases of newborns in our hospital from July 2015 to 2016 to receive the treatment of infectious pneumonia patients, and were randomly divided into control group and observation group, 50 cases in each group. The control group used routine treatment, the observation group on the basis of intravenous immunoglobulin and take corresponding nursing measures. The treatment were compared between the two groups of the total efficiency of disappearance of hospitalization time and pulmonary rales and difficulty breathing time. Results In the control group than the treatment in the observation group the total efficiency significantly comparison between the two groups of children have statistical significance(P<0.05); disappeared in the observation group hospitalization time and pulmonary rales and dyspnea was significantly better on time According to the group, there were significant differences between the two groups have statistical significance(P<0.05). Conclusion The use of Human Immunoglobulin for Intravenous Injection on the treatment of neonatal pneumonia, can effectively promote the treatment efficiency, and is helpful to the patient's recovery, worthy of promotion in clinical use.
ABSTRACT
OBJECTIVE: To determine the insoluble particles in human immunoglobulin (pH 4) for intravenous injection and human hepatitis B immunoglobulin(pH 4) for intravenous injection in both liquid and freeze-dried forms from 14 domestic manufacturers. METHODS: Thirty-two batches of human immunoglobulin products including 19 batches of human immunoglobulin (pH 4) for intravenous injection, 5 batches of human immunoglobulin (pH 4) for intravenous injection (freeze-dried), 5 batches of human hepatitis B immunoglobulin (pH 4) for intravenous injection, and 3 batches of human hepatitis B immunoglobulin(pH 4) for intravenous injection (freeze-dried) were tested by light obscuration particle count test method recommend by appendix of 2010 CHP by GWF-8JA laser particle size analyzers. Insoluble particles greater than 10 and 25 μm were counted, respectively. Microscopy counting was carried out if the test results from light blockage method did not meet the qualification criteria in 2010 ChP. Trend analysis and comparison of the results from NIFDC and enterprises were done. RESULTS: The test results of insoluble particles in 32 batches of human immunoglobulin products indicate that 90.6%(29/32) of the products complied with the requirement of 2010 ChP and the results were in agreement between NIFDC and enterprises. Unfortunately, 3 batches of human immunoglobulin(pH 4) for intravenous injection(freeze-dried) failed in light obscuration particle count test, however, they met the requirement of 2010 ChP when microscopy counting method was used. CONCLUSION: The quality control of human immunoglobulin products in China market is generally fine, and the test results from different laboratories are basically consistent. Test result of insoluble particles in freeze-dried IVIG by microscopy counting method and light obscuration particle count test method show significant difference.